NCT04462614

Possibility to Stop Perdialytic Heparin Therapy in Hemodialysed Patients With HeprAN ™ Membrane and Treated by Long-term Anticoagulation With VKA

Feasibility to Stop Perdialytic Heparin Therapy in Hemodialysed Patients With HeprAN ™ Membrane and Treated by Long-term Anticoagulation With VKA

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 49 (estimated)
• Sponsor: CHU de Reims · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Use HeprAN ™ membrane (coated with heparin) should be allow the success of dialysis sessions, with adequate dialysis parameters, in patients treated by long-term anticoagulation with VKA, without addition of heparin perdialytic. Less use of heparin (UFH or LMWH) during hemodialysis session should be allow a decrease of bleedings (moderate or major) and blood transfusions for hemodialysed patients with HeprAN ™ membrane and treated by long-term anticoagulation with VKA

Detailed description

The aim will be to study possibility of hemodialysis sessions success, without perdialytic anticoagulation but with adequate dialysis parameters (defined by the patient's Kt / V machine), in patients treated by long-term anticoagulation with VKA and dialysed with the HeprAN ™ membrane.

Conditions

• Chronic Hemolysis
• VKA
• Anticoagulants / Administration & Dosage
• Coated Materials
• Biocompatible
• Heparin / Administration & Dosage
• Membranes Artificial
• Prospective Studies
• Renal Dialysis / Methods
• Renal Insufficiency / Therapy

Interventions

Type	Name	Description
DRUG	Decrease per-dialytic heparin therapy	Week 1: maintenance's dose stop Week 2: 50% drop in the loading dose Week 3: complete cessation of heparin therapy during the session.

Timeline

• Start date: 2020-08-01
• Primary completion: 2021-01-01
• Completion: 2021-07-01
• First posted: 2020-07-08
• Last updated: 2020-07-08

Locations

1 site across 1 country: France